Cargando…
Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques
The primary cause of severe acute respiratory syndrome (SARS) is a newly discovered coronavirus(1,2,3,4,5,6,7). Replication of this SARS coronavirus (SCV) occurs mainly in the lower respiratory tract, and causes diffuse alveolar damage(2,7,8). Lack of understanding of the pathogenesis of SARS has pr...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095986/ https://www.ncbi.nlm.nih.gov/pubmed/14981511 http://dx.doi.org/10.1038/nm1001 |
_version_ | 1783510727227604992 |
---|---|
author | Haagmans, Bart L Kuiken, Thijs Martina, Byron E Fouchier, Ron A M Rimmelzwaan, Guus F van Amerongen, Geert van Riel, Debby de Jong, Ton Itamura, Shigeyuki Chan, Kwok-Hung Tashiro, Masato Osterhaus, Albert D M E |
author_facet | Haagmans, Bart L Kuiken, Thijs Martina, Byron E Fouchier, Ron A M Rimmelzwaan, Guus F van Amerongen, Geert van Riel, Debby de Jong, Ton Itamura, Shigeyuki Chan, Kwok-Hung Tashiro, Masato Osterhaus, Albert D M E |
author_sort | Haagmans, Bart L |
collection | PubMed |
description | The primary cause of severe acute respiratory syndrome (SARS) is a newly discovered coronavirus(1,2,3,4,5,6,7). Replication of this SARS coronavirus (SCV) occurs mainly in the lower respiratory tract, and causes diffuse alveolar damage(2,7,8). Lack of understanding of the pathogenesis of SARS has prevented the rational development of a therapy against this disease. Here we show extensive SCV antigen expression in type 1 pneumocytes of experimentally infected cynomolgus macaques (Macaca fascicularis) at 4 d postinfection (d.p.i.), indicating that this cell type is the primary target for SCV infection early in the disease, and explaining the subsequent pulmonary damage. We also show that prophylactic treatment of SCV-infected macaques with the antiviral agent pegylated interferon-α (IFN-α) significantly reduces viral replication and excretion, viral antigen expression by type 1 pneumocytes and pulmonary damage, compared with untreated macaques. Postexposure treatment with pegylated IFN-α yielded intermediate results. We therefore suggest that pegylated IFN-α protects type 1 pneumocytes from SCV infection, and should be considered a candidate drug for SARS therapy |
format | Online Article Text |
id | pubmed-7095986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Nature Publishing Group US |
record_format | MEDLINE/PubMed |
spelling | pubmed-70959862020-03-26 Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques Haagmans, Bart L Kuiken, Thijs Martina, Byron E Fouchier, Ron A M Rimmelzwaan, Guus F van Amerongen, Geert van Riel, Debby de Jong, Ton Itamura, Shigeyuki Chan, Kwok-Hung Tashiro, Masato Osterhaus, Albert D M E Nat Med Article The primary cause of severe acute respiratory syndrome (SARS) is a newly discovered coronavirus(1,2,3,4,5,6,7). Replication of this SARS coronavirus (SCV) occurs mainly in the lower respiratory tract, and causes diffuse alveolar damage(2,7,8). Lack of understanding of the pathogenesis of SARS has prevented the rational development of a therapy against this disease. Here we show extensive SCV antigen expression in type 1 pneumocytes of experimentally infected cynomolgus macaques (Macaca fascicularis) at 4 d postinfection (d.p.i.), indicating that this cell type is the primary target for SCV infection early in the disease, and explaining the subsequent pulmonary damage. We also show that prophylactic treatment of SCV-infected macaques with the antiviral agent pegylated interferon-α (IFN-α) significantly reduces viral replication and excretion, viral antigen expression by type 1 pneumocytes and pulmonary damage, compared with untreated macaques. Postexposure treatment with pegylated IFN-α yielded intermediate results. We therefore suggest that pegylated IFN-α protects type 1 pneumocytes from SCV infection, and should be considered a candidate drug for SARS therapy Nature Publishing Group US 2004-02-22 2004 /pmc/articles/PMC7095986/ /pubmed/14981511 http://dx.doi.org/10.1038/nm1001 Text en © Nature Publishing Group 2004 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Haagmans, Bart L Kuiken, Thijs Martina, Byron E Fouchier, Ron A M Rimmelzwaan, Guus F van Amerongen, Geert van Riel, Debby de Jong, Ton Itamura, Shigeyuki Chan, Kwok-Hung Tashiro, Masato Osterhaus, Albert D M E Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques |
title | Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques |
title_full | Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques |
title_fullStr | Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques |
title_full_unstemmed | Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques |
title_short | Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques |
title_sort | pegylated interferon-α protects type 1 pneumocytes against sars coronavirus infection in macaques |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095986/ https://www.ncbi.nlm.nih.gov/pubmed/14981511 http://dx.doi.org/10.1038/nm1001 |
work_keys_str_mv | AT haagmansbartl pegylatedinterferonaprotectstype1pneumocytesagainstsarscoronavirusinfectioninmacaques AT kuikenthijs pegylatedinterferonaprotectstype1pneumocytesagainstsarscoronavirusinfectioninmacaques AT martinabyrone pegylatedinterferonaprotectstype1pneumocytesagainstsarscoronavirusinfectioninmacaques AT fouchierronam pegylatedinterferonaprotectstype1pneumocytesagainstsarscoronavirusinfectioninmacaques AT rimmelzwaanguusf pegylatedinterferonaprotectstype1pneumocytesagainstsarscoronavirusinfectioninmacaques AT vanamerongengeert pegylatedinterferonaprotectstype1pneumocytesagainstsarscoronavirusinfectioninmacaques AT vanrieldebby pegylatedinterferonaprotectstype1pneumocytesagainstsarscoronavirusinfectioninmacaques AT dejongton pegylatedinterferonaprotectstype1pneumocytesagainstsarscoronavirusinfectioninmacaques AT itamurashigeyuki pegylatedinterferonaprotectstype1pneumocytesagainstsarscoronavirusinfectioninmacaques AT chankwokhung pegylatedinterferonaprotectstype1pneumocytesagainstsarscoronavirusinfectioninmacaques AT tashiromasato pegylatedinterferonaprotectstype1pneumocytesagainstsarscoronavirusinfectioninmacaques AT osterhausalbertdme pegylatedinterferonaprotectstype1pneumocytesagainstsarscoronavirusinfectioninmacaques |